During a trial, one patient died by suicide so patients should also be monitored for depression and suicidal thoughts while taking it, according to the FDA.
GLP-1 Companion Products Market At a Glance Key Growth Drivers, Constraints, and Opportunities Key Factors Driving Growth The soaring popularity of GLP-1 therapies for diabetes and obesity has led to a surge in demand for companion products to augment patient adherence and improve clinical outcomes
Later retracted due to data fabrication concerns involving Kawas and Harding [Benoist et al., 2014 RETRACTED]
Discovery work characterised it as roughly 0.4 as active as native GLP-1, 0.3 as active as native glucagon and about 8.9 as active at the GIP receptor [6]
Type 2 Diabetic Patients Are you a sufferer of poor insulin production
If the liquid becomes cloudy or discolored, it is a sign that the medication has likely been compromised and should be discarded